ALTG 16/005 OSCILLATE: Alternating Osimertinib and Gefitinib in patients with EGFR T790M positive NSCLC – B Solomon

This study aims to determine the efficacy, safety, and feasibility of alternating osimertinib and gefitinib in patients with EGFR-T790M mutation positive NSCLC. Planned recruitment is 45 patients from 15 sites. The protocol has been finalised and funding approved. Central ethics submission was completed in March 2017, feasibility will be circulated in Q2 2017 and the anticipated FPI will be in Q3 2017.

Contact: OSCILLATE@ctc.usyd.edu.au

Upcoming Events
  1. ***UPDATED*** ALTG Members’ Meeting, Sydney NSW

    November 24
  2. ***UPDATED*** Shine A Light Dinner, Sydney NSW

    November 24 @ 6:00 pm - 9:00 pm AEST
  3. ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW

    November 25 @ 9:00 am - 5:00 pm UTC+10